Literature DB >> 6208891

Assessment and hormonal treatment of the luteal phase of in vitro fertilization cycles.

J L Yovich, J D Stanger, J M Yovich, A I Tuvik.   

Abstract

Luteal phase lengths and hormonal profiles (progesterone, oestradiol-17 beta, beta HCG and prolactin) have been documented in 77 cases derived from a series of patients undergoing IVF. Nineteen pregnancies were generated during this series and 12 healthy infants have already been delivered. Luteal phase lengths were 14.5 +/- 0.5 days with 14.3% demonstrating mid-luteal progesterone levels of less than 31 nmols/l, considered to be low for successful conception. A random study of luteal support regimens comparing HCG or medroxyprogesterone acetate (MPA) with nil therapy was studied in a series of 44 consecutive embryo transfers during which 10 pregnancies were achieved. No difference was noted in the pregnancy rates for the 3 groups but the pregnancy outcome was better in those who had HCG support and this was more apparent in the overall series of 19 pregnancies. A significant luteotrophic effect was noted with HCG support regimens whilst MPA appeared to have a luteal suppressant action. Six pregnancies which aborted with blighted ova were derived from cycles in which the luteal phase progesterone levels were low raising the possibility that a poor hormonal environment may predispose to blighted ova.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6208891     DOI: 10.1111/j.1479-828x.1984.tb01472.x

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  5 in total

1.  A short luteal phase in cycles stimulated with clomiphene and human menopausal gonadotropin for in vitro fertilization.

Authors:  T Laatikainen; H Kurunmäki; A Koskimies
Journal:  J In Vitro Fert Embryo Transf       Date:  1988-02

Review 2.  Luteal phase support for assisted reproduction cycles.

Authors:  Michelle van der Linden; Karen Buckingham; Cindy Farquhar; Jan A M Kremer; Mostafa Metwally
Journal:  Cochrane Database Syst Rev       Date:  2015-07-07

3.  Fetal abnormality (Goldenhar syndrome) occurring in one of triplet infants derived from in vitro fertilization with possible monozygotic twinning.

Authors:  J L Yovich; J D Stanger; A A Grauaug; G G Lunay; P Hollingsworth; M T Mulcahy
Journal:  J In Vitro Fert Embryo Transf       Date:  1985-03

4.  DHEA Supplementation Confers No Additional Benefit to that of Growth Hormone on Pregnancy and Live Birth Rates in IVF Patients Categorized as Poor Prognosis.

Authors:  Kevin N Keane; Peter M Hinchliffe; Philip K Rowlands; Gayatri Borude; Shanti Srinivasan; Satvinder S Dhaliwal; John L Yovich
Journal:  Front Endocrinol (Lausanne)       Date:  2018-01-31       Impact factor: 5.555

5.  Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis.

Authors:  Kevin N Keane; John L Yovich; Anahita Hamidi; Peter M Hinchliffe; Satvinder S Dhaliwal
Journal:  BMJ Open       Date:  2017-10-08       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.